1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Bristol Myers Squibb Corporate Giving & Independent Medical Education Funding - Oncology/Hematology is sponsored by Bristol Myers Squibb. Provides year-round corporate grants and independent medical education (IME) support, focusing on health equity initiatives and priority oncology/hematology areas to advance patient care, remove barriers to treatment, and improve outcomes for diverse and underserved populations.
Supports program development, educational materials, conference participation, patient-focused initiatives, community outreach, and advocacy projects.
Get alerted about grants like this
Save a search for “Bristol Myers Squibb” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Non-profit or academic organizations working in disease awareness & education, access to quality care, patient support services, or health-equity policy and advocacy within BMS therapeutic areas. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Transforming access to sickle cell care in sub-Saharan Africa is sponsored by Bristol Myers Squibb Foundation. The Bristol Myers Squibb Foundation, in partnership with Baylor College of Medicine Global Health and Texas Children's Global HOPE program, launched an initiative in October 2024 to transform pediatric SCD care in Sub-Saharan Africa. The initiative focuses on building local healthcare capacity and integrating lifesaving SCD interventions into primary health services. Initial launches are in Tanzania and Uganda, with a phased approach for a broader pan-African program.
Sickle Cell Disease program (part of Pediatric Cancers and Blood Disorders focus area) is sponsored by Bristol Myers Squibb Foundation. The BMS Foundation, in partnership with Baylor College of Medicine Global Health and Texas Children's Global HOPE Program, supports initiatives to transform pediatric care for sickle cell disease (SCD) in sub-Saharan Africa. This includes building local healthcare capacity and integrating SCD interventions into primary health services.
Bristol Myers Squibb Corporate Giving & Independent Medical Education Funding is sponsored by Bristol Myers Squibb. BMS provides corporate grants and independent medical education (IME) support focusing on health equity initiatives and priority oncology/hematology areas to advance patient care, remove barriers to treatment, and improve outcomes for diverse and underserved populations.